Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives $32.00 Consensus PT from Analysts

Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) have received a consensus recommendation of “Buy” from the seven analysts that are presently covering the firm, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have issued a report on the […]

Leave a Reply

Your email address will not be published.

Previous post Flutter Entertainment plc (NYSE:FLUT) Given Average Rating of “Moderate Buy” by Brokerages
Next post Dynatronics (NASDAQ:DYNT) vs. Universal Media Group (OTCMKTS:UMGP) Head to Head Contrast